Volume 21, Number 5—May 2015
Postmortem Stability of Ebola Virus
Highlight and copy the desired format.
|EID||Prescott JB, Bushmaker T, Fischer RJ, Miazgowicz K, Judson SD, Munster VJ. Postmortem Stability of Ebola Virus. Emerg Infect Dis. 2015;21(5):856-859. https://dx.doi.org/10.3201/eid2105.150041|
|AMA||Prescott JB, Bushmaker T, Fischer RJ, et al. Postmortem Stability of Ebola Virus. Emerging Infectious Diseases. 2015;21(5):856-859. doi:10.3201/eid2105.150041.|
|APA||Prescott, J. B., Bushmaker, T., Fischer, R. J., Miazgowicz, K., Judson, S. D., & Munster, V. J. (2015). Postmortem Stability of Ebola Virus. Emerging Infectious Diseases, 21(5), 856-859. https://dx.doi.org/10.3201/eid2105.150041.|
The ongoing Ebola virus outbreak in West Africa has highlighted questions regarding stability of the virus and detection of RNA from corpses. We used Ebola virus–infected macaques to model humans who died of Ebola virus disease. Viable virus was isolated <7 days posteuthanasia; viral RNA was detectable for 10 weeks.
The ongoing outbreak of Ebola virus (EBOV) infection in West Africa highlights several questions, including fundamental questions surrounding human-to-human transmission and stability of the virus. More than 20,000 cases of EBOV disease (EVD) have been reported, and >8,000 deaths have been documented (1). Human-to-human transmission is the principal feature in EBOV outbreaks; virus is transmitted from symptomatic persons or contaminated corpses or by contact with objects acting as fomites (2). Contact with corpses during mourning and funeral practices, which can include bathing the body and rinsing family members with the water, or during the removal and transportation of bodies by burial teams has resulted in numerous infections (3).
Assessing the stability of corpse-associated virus and determining the most efficient sampling methods for diagnostics will clarify the safest practices for handling bodies and the best methods for determining whether a person has died of EVD and presents a risk for transmission. To facilitate diagnostic efforts, we studied nonhuman primates who died of EVD to examine stability of the virus within tissues and on body surfaces to determine the potential for transmission, and the presence of viral RNA associated with corpses.
We studied 5 cynomolgus macaques previously included in EBOV pathogenesis studies and euthanized because of signs of EVD and viremia. Two animals were infected with EBOV-Mayinga and 3 with a current outbreak isolate (Makona-WPGC07) (4).
Immediately after euthanasia, multiple samples were collected: oral, nasal, ocular, urogenital, rectal, skin, and blood (pooled in the body cavity) swab samples and tissue biopsy specimens from the liver, spleen, lung, and muscle. Swabs were placed in 1 mL of culture medium and tissue samples were placed in 500 μL of RNAlater (QIAGEN, Valencia, CA, USA), or an empty vial for titration, before freezing at −80°C. Carcasses were placed in vented plastic containers in an environmental chamber at 27°C and 80% relative humidity throughout the study to mimic conditions in West Africa (5). At the indicated time points (<9 days for 2 animals and 10 weeks for 3 animals), swab and tissue samples were obtained and used for EBOV titration on Vero E6 cells to quantify virus or for quantitative reverse transcription PCR (qRT-PCR) (40 cycles) to measure viral RNA, as reported (6,7).
Viral RNA was detectible in all swab samples and tissue biopsy specimens at multiple time points (Figure 1). For swab samples (Figure 1, panel A), the highest amount of viral RNA was in oral, nasal, and blood samples; oral and blood swab specimens consistently showed positive results for all animals until week 4 for oral specimens and week 3 for blood, when 1 animal was negative for each specimen type. Furthermore, oral swab specimens had the highest amount of viral RNA after the first 2 weeks of sampling, although after the 4-week sampling time point, some samples from individual animals were negative.
In all samples, RNA was detectable sporadically for the entire 10-week period, except for blood, which had positive results for <9 weeks. Tissue samples were more consistently positive within the first few weeks after euthanasia (Figure 1, panel B). All samples from the liver and lung were positive for the first 3 weeks, and spleen samples were positive for the first 4 weeks, at which time lung and spleen samples were no longer tested because of decay and scarcity of tissue. Muscle sample results were sporadic: a sample from 1 animal was negative at the 1-day time point and at several times throughout sampling.
Viable EBOV was variably isolated from swab from all sampling sites. Among blood samples, those from the body cavity had the highest virus titer (2 × 105 50% tissue culture infectious doses/mL) and longest-lasting isolatable virus (7 days posteuthanasia) (Figure 2, panel A). Consistent with the qRT-PCR results, for swab samples, oral and nasal sample titers were highest, followed by those for blood samples, and relatively high titers were observed <4 days posteuthanasia (Figure 2, panel B). Similar to the qRT-PCR experiments, virus titers were higher in tissue samples than in swab samples but were not as sustained; all tissue samples were positive at day 3 posteuthanasia but negative by day 4.
The efficiency of detecting EBOV from corpse samples has not been systematically studied; this information is needed for interpreting results for diagnostic samples for epidemiologic efforts during outbreaks. We showed that viral RNA is readily detectable from oral and blood swab specimens for <3 weeks postmortem from a monkey carcass that was viremic at the time of death, in environmental conditions similar to those during current outbreak (5).
The stability of the target RNA used for RT-PCR is more robust than that of viable virus because degradation of any part of the genome (or proteins and lipids) would compromise the ability of the virus to replicate. Thus, the ability to isolate replicating virus in cell culture from postmortem materials was much less sensitive than detection of viral RNA by qRT-PCR. The sensitivity for quantitating infectious virus is probably lowered because of limitations in isolation efficiency on cell culture and necessary dilutions of tissues for homogenization for titration. Nonetheless, we detected viable virus <7 days posteuthanasia in swab specimens and 3 days in tissues, and showed that infectious virus is present at least until these times. Because virus titers decreased relatively sharply, despite sensitivity issues, it is unlikely that viable virus persists for times longer than we measured.
Humans who die of EVD typically have high levels of viremia, suggesting that most fresh corpses contain high levels of infectious virus, similar to the macaques in this study (9). Furthermore, family members exposed to EVD patients during late stages of disease or who had contact with deceased patients have a high risk for infection (2). The presence of viable EBOV and viral RNA in body fluids of EVD patients has been studied, and oral swabbing has been shown to be effective for diagnosis of EVD by RT-PCR compared with testing of serum samples from the same persons (10,11). However, detection limits for diagnostic swab samples are unknown for early phases of EVD, and blood sampling is probably more sensitive and reliable for antemortem diagnostics and should be used whenever possible, which has also been shown with closely related Marburg virus (12).
Although these studies included data from outbreak situations, they are limited in their sampling numbers, swabbing surfaces, and time course, and it is unknown how predictive they are for samples collected postmortem. It is essential to stress that swab samples should be obtained by vigorous sampling to acquire sufficient biologic material for testing, and development of a quality-control PCR target (housekeeping gene target) would be beneficial for sample integrity assessment, which is a limitation of this study.
In summary, we present postmortem serial sampling data for EBOV-infected animals in a controlled environment. Our results show that the EBOV RT-PCR RNA target is highly stable, swabbing upper respiratory mucosa is efficient for obtaining samples for diagnostics, and tissue biopsies are no more effective than simple swabbing for virus detection. These results will directly aid interpretation of epidemiologic data collected for human corpses by determining whether a person had EVD at the time of death and whether contact tracing should be initiated. Furthermore, viable virus can persist for >7 days on surfaces of bodies, confirming that transmission from deceased persons is possible for an extended period after death. These data are also applicable for interpreting samples collected from remains of wildlife infected with EBOV, especially nonhuman primates, and to assess risks for handling these carcasses.
Dr. Prescott is a research fellow in the Virus Ecology Unit at Rocky Mountain Laboratories, Hamilton, Montana. He is currently involved in the Ebola virus outbreak at the combined Centers for Disease Control and Prevention/National Institutes of Health diagnostic laboratory, Monrovia, Liberia. His research interests include the immune response, transmission, and modeling of viral hemorrhagic fevers.
We thank Darryl Falzarano and Andrea Marzi for use of animal carcasses upon completion of their studies and Anita Mora for providing assistance with graphics.
This study was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
- Centers for Disease Control and Prevention. Ebola hemorrhagic fever [cited 2015 Jan 3]. http://www.cdc.gov.ezproxy.nihlibrary.nih.gov/vhf/ebola/
- Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis. 1999;179(Suppl 1):S87–91 .
- Khan AS, Tshioko FK, Heymann DL, Le Guenno B, Nabeth P, Kerstiëns B, The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. J Infect Dis. 1999;179(Suppl 1):S76–86.
- Hoenen T, Groseth A, Feldmann F, Marzi A, Ebihara H, Kobinger G, Complete genome sequences of three Ebola virus isolates from the 2014 outbreak in West Africa. Genome Announc. 2014;2:e01331–14.
- Ng S, Cowling B. Association between temperature, humidity and ebolavirus disease outbreaks in Africa, 1976 to 2014. Euro Surveill. 2014;19:20892 .
- Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Vesicular stomatitis virus–based Ebola vaccines with improved cross-protective efficacy. J Infect Dis. 2011;204(Suppl 3):S1066–74.
- Ebihara H, Rockx B, Marzi A, Feldmann F, Haddock E, Brining D, Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J Infect Dis. 2011;204(Suppl 3):S991–9.
- Finney DJ. Statistical method in biological assay. New York: Macmillian Publishing Co., Inc.; 1978. p. 394–8.
- Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, Vincent M, Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription–PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol. 2004;78:4330–41.
- Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis. 2007;196(Suppl 2):S142–7.
- Formenty P, Leroy EM, Epelboin A, Libama F, Lenzi M, Sudeck H, Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin Infect Dis. 2006;42:1521–6.
- Grolla A, Jones SM, Fernando L, Strong JE, Ströher U, Möller P, The use of a mobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg outbreak in Angola. PLoS Negl Trop Dis. 2011;5:e1183.
FiguresCite This Article
- Page created: April 18, 2015
- Page last updated: April 18, 2015
- Page last reviewed: April 18, 2015
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)